pyrroles has been researched along with Mucositis in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Rahman, O; Fouad, M | 1 |
| Chan, A; Chau, NM; Chue, XP; Ho, HK; Kanesvaran, R; Tan, MH; Teo, YL; Wee, HL | 1 |
| Charles, LP; DeAnnuntis, L; Escudier, B; Gore, ME; Hariharan, S; Motzer, RJ; Porta, C; Rini, BI; Yang, L | 1 |
| Beaumont, JL; Cella, D; Diaz, J; Khan, S; Lai, JS | 1 |
| Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
| Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH | 1 |
| Baggstrom, MQ; Baker, S; Crawford, JA; Edelman, MJ; Feliciano, J; Gu, L; Hahn, O; Novotny, P; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, XF | 1 |
| Andrieu, JM; Azizi, M; Banu, E; Chedid, A; Fournier, L; Helley, D; Medioni, J; Mejean, A; Oudard, S; Scotte, F | 1 |
| Baak-Pablo, RF; Boven, E; Eechoute, K; Gelderblom, H; Guchelaar, HJ; Haanen, JB; Mathijssen, RH; Reyners, AK; van der Straaten, T; van der Veldt, AA; van Erp, NP; Wessels, JA | 1 |
| Eufinger, H; Hoefert, S | 1 |
| Berg, BC; Chow, S; Suwattee, P; Warshaw, EM | 1 |
1 review(s) available for pyrroles and Mucositis
| Article | Year |
|---|---|
Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Eruptions; Hand-Foot Syndrome; Humans; Indoles; Mucositis; Pyrroles; Sunitinib | 2015 |
2 trial(s) available for pyrroles and Mucositis
| Article | Year |
|---|---|
Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indazoles; Indoles; Kidney Neoplasms; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Risk Assessment; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2016 |
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Fatigue; Female; Humans; Hypertension; Indoles; Intention to Treat Analysis; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mucositis; Neoplasm Staging; Neutropenia; Platinum Compounds; Pyrroles; Quality of Life; Sunitinib; Survival Rate; Thrombocytopenia | 2017 |
8 other study(ies) available for pyrroles and Mucositis
| Article | Year |
|---|---|
Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Prospective Studies; Pyrroles; Singapore; Sunitinib | 2015 |
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
Topics: Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Dysgeusia; Dyspepsia; Fatigue; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Mucositis; Nausea; Pyrroles; Stomatitis; Sunitinib; Time Factors | 2016 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing Countries; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Prospective Studies; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; White People; Young Adult | 2016 |
Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
Topics: Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Pancreatic Neoplasms; Pyrroles; Salvage Therapy; Sunitinib | 2009 |
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constitutive Androstane Receptor; Cytochrome P-450 CYP1A1; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Haplotypes; Humans; Indoles; Leukopenia; Male; Middle Aged; Mucositis; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Risk Factors; Sunitinib; Young Adult | 2009 |
Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Carcinoma, Renal Cell; Diphosphonates; Humans; Indoles; Injections, Intravenous; Kidney Neoplasms; Mandibular Diseases; Middle Aged; Mucositis; Osteonecrosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Risk Factors; Stomatitis; Sunitinib; Tooth Extraction | 2010 |
Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.
Topics: Antineoplastic Agents; Carcinoid Tumor; Drug Eruptions; Erythema; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Humans; Immunosuppressive Agents; Indoles; Male; Middle Aged; Mouth Mucosa; Mucositis; Pyrroles; Risk Assessment; Skin Diseases, Vesiculobullous; Sunitinib; Treatment Outcome | 2008 |